Toward a More Robust Regulatory Pathway — 3 Qs with Carmell Therapeutics’ CEO Randy Hubbell
Press Release
, December 26th, 2018
Carmell Therapeutics President & CEO, Randy Hubbell, to Present at Biotech Showcase™ 2019 in San Francisco
Press Release
, December 20th, 2018
ALung Announces Significant Progress in its Hemolung Clinical Trial Programs
Press Release
, December 10th, 2018
Cognition Therapeutics Expands Industry-Leading Expertise in Research and Clinical Use of Biomarkers of Alzheimer’s Disease
Press Release
, November 27th, 2018
President and CEO, Randy Hubbell delivers a corporate presentation at the Investival Showcase at the Waldorf Hilton Hotel in London
Press Release
, November 13th, 2018
Carmell Therapeutics President & CEO, Randy Hubbell, to Present at Investor and MedTech Conferences in November
Press Release
, November 8th, 2018
Cognition Therapeutics Initiates Patient Dosing in Phase 2 SHINE Study of Elayta™ in Patients with Mild-to-Moderate Alzheimer’s Disease
Press Release
, November 8th, 2018
Wellbridge Health Unveils First-of-its-Kind Digital Care Management Program for End-Stage Renal Disease: No-Risk Pilot Ready for Insurers and Employers
Press Release
, November 1st, 2018
Cognition Therapeutics to Sponsor Third International Symposium on Sigma-2 Receptors: Role in Health and Disease during the Society for Neuroscience Annual Meeting
Press Release
, October 24th, 2018